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We conducted a retrospective study of patients with cuta-
neous myeloid sarcoma, from 2 tertiary care institutions. 
Eighty-three patients presented, with a mean age of 52 
years. Diagnosis of myeloid sarcoma in the skin was diffi-
cult due to the low frequency of myeloperoxidase and/or 
CD34+ cases (56% and 19% of tested cases, respectively). 
Seventy-one of the 83 patients (86%) had ≥ 1 bone mar-
row biopsy. Twenty-eight (39%) had acute myeloid leu-
kemia with monocytic differentiation. Twenty-three had 
other de novo acute myeloid leukemia subtypes. Thirteen 
patients had other myeloid neoplasms, of which 4 ultima-
tely progressed to an acute myeloid leukemia. Seven had 
no bone marrow malignancy. Ninety-eight percent of 
the patients received chemotherapy, and approximately 
89% died of causes related to their disease. Cutaneous 
myeloid sarcoma in most cases represents an aggressive 
manifestation of acute myeloid leukemia. Diagnosis can 
be challenging due to lack of myeloblast-associated an-
tigen expression in many cases, and difficulty in distin-
guishing monocyte-lineage blasts from neoplastic and 
non-neoplastic mature monocytes. Key words: cutaneous 
myeloid sarcoma; chloroma; myeloid sarcoma; mono­
blastic sarcoma.
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The World Health Organization defines myeloid sarcoma 
as “a tumor mass consisting of myeloid blasts with or 
with out maturation occurring at an anatomical site other 
than the bone marrow” (1). Although the skin is identified 
as a common site of involvement of myeloid sarcoma, 
studies of cutaneous myeloid sarcoma (CMS) are relati-
vely lacking. A large study consisting of cases presenting 
in the skin is desirable to evaluate the demographic, 
clinical, and histopathologic properties of CMS, and the 
potential impact of the microanatomy and cytokine milieu 
of the skin in the presentation of cutaneous leukemias.
We report the results of a retrospective study of 83 
patients presenting with CMS over a 19-year period at 
2 tertiary care institutions in the Midwest United States. 
We emphasize the demographics, clinical presentation, 
and pathologic workup of these patients, and their re-
sponse to therapy. 
METHODS
The study was performed with the joint approval of the In-
stitutional Review Boards of the Saint Louis University and 
Washington University Schools of Medicine. 
Search parameters
A search of the electronic databases of the Department of 
Dermatology, Division of Dermatopathology, Saint Louis 
University, and the Section of Anatomic and Molecular Patho-
logy, Department of Pathology and Immunology, Washington 
University, was performed. Typical patient demographic data 
was collected (date of birth, gender, and race) along with der-
matological information regarding lesion size, morphology, and 
anatomic site. In addition, data concerning other anatomic sites 
of involvement, patient treatment regimen, clinical course, and 
survival status were also recorded.
The study also describes the bone marrow in comparison 
with the cutaneous involvement of myeloid blasts. This was 
accomplished by including bone marrow aspirate immunohisto-
chemistry, histochemistry, flow cytometry, phenotype of the 
myeloid leukemia by flow cytometry, marrow cellularity, 
myeloid:erythroid ratio, myeloid blast cell percentage, along 
with enzyme cytochemical analysis results. Whenever available, 
karyotype, fluorescence-in-situ-hybridization, and the results 
of molecular genetic testing were also included. 
Chart review
The charts of all patients were reviewed for evaluation of the 
following parameters: age at initial presentation, gender, race, 
site(s) of involvement, clinical description of lesion(s), temporal 
relationship of CMS to acute myeloid leukemia (AML) (i.e. did 
the diagnosis of CMS precede, coincide, or follow the diagnosis 
of AML), therapy, and outcome. For patients who were eva-
luated at Saint Louis University or Washington University and 
treated elsewhere, additional clinical follow-up was obtained 
from the referring clinicians.
Pathologic review
In all patients, the diagnostic biopsies of the skin, bone marrow, 
and other sites of involvement were reviewed for all available 
cases. Notes were made of the histopathologic features, im-
munohistochemistry, and flow cytometry of all tested cases. 
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Statistical analysis
The patient demographics, cutaneous lesion presentation 
characteristics, dermatopathologic findings, and bone marrow 
characteristics of patients with CMS were described using 
frequencies (%) for categorical level variables and measures 
of central tendency (means ± standard deviation (SD)) for con-
tinuous level variables.
Additionally comparisons were made to identify if the charac-
teristics vary between length of time from diagnosis of AML, 
age, race, site of involvement, number of lesions, and other 
important factors. Chi-square analysis, independent samples 
t-test, and analysis of variance between groups (ANOVA) 
were utilized to analyze the data. All analyses were defined as 
statistically significant when α < 0.05. SPSS software, version 
16 (Chicago, Illinois) was used for the analysis.
RESULTS
Eighty-three patients were identified in the search of 
the laboratory information systems of both institutions. 
Although CMS has a male predominance (50 males 
and 33 females, p = 0.62). The vast majority of patients 
were white (86% of patients), and a wide age range 
was identified, with age at onset of cutaneous disease 
range between 2 weeks–89 years old. The lesions were 
discrete in all cases, and most often were described 
as papules, nodules, or plaques. They presented most 
commonly on the torso (39% of cases), followed by the 
upper extremities (24%), lower extremities (21%), and 
head and neck (16%). In 34 cases the patients had a 
diagnosis of bone marrow-based AML and a sufficient 
clinical history allowed a temporal relationship to be 
established between the two diagnoses. CMS preceded 
the bone marrow diagnosis of AML in 6 (18 %) cases, 
followed it in 15 (44%), and was coincident with the 
diagnosis of AML in the bone marrow (defined as oc-
curring within 2 weeks of the bone marrow diagnosis) 
in 13 (38%). Most patients had disease limited to the 
skin and bone marrow; however, 18/83 (22%) of the 
patients experienced involvement of sites outside the 
skin and bone marrow, most commonly the central ner-
vous system (6 cases) and lymph nodes (6 cases). Other 
sites of involvement included the gastrointestinal tract, 
liver, and lung (3 patients each), and the spleen, oral 
mucosa, and testes (2 patients each). Fifteen patients 
had involvement of the bone marrow by an AML with 
monocytic differentiation (French-American-British 
classification of AML (FAB): M4 or M5). Using the 
“registry” with 83 cases of CMS, the one-year mortality 
status was determined for 59 (or 71.1%) of cases. Of 
these 59 cases, 86.4% were deceased one-year after 
the diagnosis date. Of the patients who died during 
the observed period, the mean number of survival days 
after the diagnosis date was 227 ± 319 (range 14–1,561, 
median  64, 25–75% 31–275). The death date was unk-
nown for one of the 51 cases known to be deceased. 
The mean age at CMS diagnosis was 54.9 ± 20 years, 
based on 75 cases with known age at CMS diagnosis. 
Women were younger than men at age of diagnosis 
(49.5 vs 58.4), but this was not statistically significant 
(p = 0.062). No difference was observed in age at di-
agnosis by race (white vs. black vs. other). The pos-
sible association between patient age at diagnosis and 
survival days was explored by calculating the Pearson 
correlation coefficient. Among the 51 patients who 
were deceased, there was no correlation between age 
at diagnosis and survival days (correlation coefficient 
of 0.012, p = 0.993). The registry includes 18 cases who 
survived for > 1 year. Among these 18 cases, the mean 
age at diagnosis was 51.6 ± 22 among the 17 subjects 
with known age information. 61% of survivors were 
male; 61% were Caucasian. There was no statistically 
significant difference between mean age at diagnosis 
(p = 0.352) or gender (p = 0.800) between one-year 
survivors and deceased cases. When examined for sur-
vival at the 60-day mark, the same results persisted: no 
differences were seen between mean age at diagnosis 
or gender. Four patients were autopsied, all of whom 
had noncutaneous sites of involvement which had not 
been detected antemortem. 
The skin lesions had a variable microscopic appearan-
ce. The overlying epidermis was essentially unremarka-
ble in all cases. In all cases the malignant cells involved 
the superficial and deep dermis. The cells comprising the 
infiltrate were clearly identifiable as blasts in most cases 
by their immature cytomorphology, abundant mitotic 
activity, dispersed nuclear chromatin with nucleoli, and 
scattered apoptotic cells. This cytomorphology was a 
particularly important consideration for cases in which 
the infiltrate was relatively subtle and/or predominantly 
perivascular and could simulate a benign process in-
flammatory skin disorder. Eleven cases demonstrated 
extension of blasts through the dermis into the under-
lying subcutis. In most cases the pattern of infiltration 
was perivascular, periadnexal, and interstitial, with 
relative preservation of the microanatomy of the dermis 
(Fig. 1). In contrast, 20 cases demonstrated an overall 
pattern of diffuse involvement, with destruction of the 
normal microanatomic features of the dermis (Fig. 2). 
In a statistical comparison of cases with diffuse growth 
versus others, there were no significant differences re-
garding survival, and the demographic and phenotypic 
properties of both groups were similar.
Due to the retrospective nature of this study, in which 
the cases were initially reviewed by a large number 
of hematopathologists and dermatopathologists, the 
diagnostic approach to the skin biopsies was highly 
variable. The myeloid lineage of all cases was subse-
quently established by us (2). Cases initially presenting 
in the bone marrow with secondary involvement of 
the skin frequently had a minimal workup, since the 
differential diagnosis was very limited. Nineteen cases 
with involved skin biopsies and a prior bone marrow 
diagnosis of AML were evaluated by a hematoxylin 
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and eosin-stained section without additional studies. In 
an additional 19 patients, evaluated by a hematoxylin 
and eosin-stained section and a chloroacetate esterase 
(Leder) stained section, the blasts were Leder nega-
tive. The remaining cases had immunohistochemistry 
analysis as part of their workup, including lysozyme 
(positive in 14/14[100%] of tested cases), myelo-
peroxidase (20/36, 56%), CD68 (14/14, 100%), and 
CD34 (3/16, 19%). A comprehensive list 
of antibodies reviewed in this study is 
listed in Table SI (available from http://
www.medicaljournals.se/acta/content/?d
oi=10.2340/00015555-1458). Of note, se-
veral cases demonstrated aberrant expres-
sion of markers of other lineages, which 
is a well-known phenomenon in AML 
but may lead to an erroneous diagnosis, 
particularly in patients with a limited 
immunohistochemical workup and/or 
lack of clinical history. Aberrant expres-
sion of B-lymphoid-related antigens was 
rare, limited to CD20 expression in one 
of 20 tested cases. This unusual finding 
has been previously noted in AML (3) 
Aberrant expression of T- and NK-cell 
antigens was more frequent. CD5 expres-
sion was noted in 1 of 2 tested cases, 
which has been reported in rare cases 
of AML (4). CD7 was positive in 1 of 5 
tested cases; however the diagnosis of 
T-cell lymphoma was not of diagnostic 
concern based on the absence of expres-
sion of other T-cell associated antigens, 
and the supporting clinical history. CD56 
was expressed in 5 of 6 tested cases, 
and in 3 of these cases was coexpressed 
with CD4 (Fig. S1; available from http://
www.medicaljournals.se/acta/content/?
doi=10.2340/00015555-1458). The dif-
ferential diagnosis for such cases, parti-
cularly in patients presenting with skin lesions, includes 
blastic plasmacytoid dendritic cell neoplasm (formerly 
referred to as blastic natural killer cell lymphoma and 
agranular CD4+/CD56+ hematodermic neoplasm). In 
such patients, a more extensive immunohistochemical 
workup may be warranted, and the clinical history may 
be critical. All 3 patients with CD4+/CD56+ blasts had 
a prior history of AML (2 with acute myelomonocytic 
Fig. 1. Myeloid sarcoma, example of a case (A) with focal architecture, characterized by 
periadnexal, perivascular, and perifollicular growth with sparing of dermal microanatomic 
structures, and (B) extension into the subcutaneous fat (H&E, original magnifications ×200). 
(C, D) Blasts are large with high nuclear: cytoplasmic ratio, dispersed nuclear chromatin, and 
prominent nucleoli; mitoses are prominent (H&E, original magnification ×400).
Fig. 2. Myeloid sarcoma; example of a 
case with diffuse growth, characterized 
by destruction of dermal microanatomic 
structures (hematoxylin and eosin, 
original magnifications × 200, × 400). 
Leder histochemistry is negative 
in blasts (original magnification 
× 400). Immunohistochemistry (× 400) 
demonstrates the blasts to express CD7, 
CD117, and CD34 (partial).
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leukemia, one with relapsed acute AML in which the 
original material could not be reviewed) and had blasts 
which also expressed lysozyme and CD68. Although 
rare CD68+ cases of blastic plasmacytoid dendritic cell 
neoplasm have been reported in the literature, lysozyme 
expression is indicative of myeloid origin for the ma-
lignant cells. 
Of the 83 patients 71 (85%) had at least one bone 
marrow biopsy available for review. Twenty-nine pa-
tients (41%) had an AML with monocytic differentiation 
(15 acute myelomonocytic leukemias [FAB: M4], 14 
acute monoblastic/ monocytic leukemias [FAB: M5]). 
Thirty-five patients had other AML subtypes. Many 
AML cases could not be further subclassified because 
1) a disease-defining cytogenetic abnormality was not 
present and 2) enzyme cytochemical analysis of the 
blasts was not performed. Thirteen patients had myelo-
proliferative neoplasms, myelodysplastic syndromes, or 
overlap diseases (5 cases of chronic myelomonocytic 
leukemia), of which 5 ultimately progressed to an 
AML Seven patients had no evidence of bone marrow 
involvement by a malignancy. A comprehensive list of 
bone marrow diagnoses is listed in Table II (available 
from http://www.medicaljournals.se/acta/content/?d
oi=10.2340/00015555-1458). Cytogenetic and/or mo-
lecular genetic results were abnormal in 23/29 (79%) of 
tested individuals and revealed the following: 2 patients 
with loss of chromosome 7, 2 patients with loss of the 
long arm of chromosome 7, 7 patients with trisomy of 
chromosome 8, and 5 patients with abnormalities of 
chromosome 11q23 involving the mixed lineage leukemia 
(MLL) locus. Nine patients had multiple nonspecific 
structural and/or numerical chromosomal abnormali-
ties. Five patients had normal conventional cytogenetic 
analysis. Fluorescence in situ-hybridization confirmed 
the findings of MLL rearrangement in 4 patients and 
trisomy of chromosome 8 in 4 patients, and revealed 
low-level abnormal loss of the RUNX1 (formerly known 
as AML1) locus in one patient with normal conventional 
cytogenetics.
Due to the retrospective nature of the specimens, 
analysis of the degree of phenotypic concordance bet-
ween the skin and bone marrow specimens is limited. 
However, the available data support that the blast im-
munophenotype is retained at both sites (Tables I and 
II), both in cases with flow cytometric analysis of the 
bone marrow and in cases with immunohistochemical 
analysis of the bone marrow. In addition, there was only 
one case with discordant CD117 immunohistochemistry, 
a case of AML derived from prior chronic myelomo-
nocytic leukemia. 
DISCUSSION
The skin is one of the most common sites of involvement 
by myeloid sarcoma. The mechanism responsible for the 
migration of myeloid blasts to the skin is poorly under-
stood, but is hypothesized to be the result of the expres-
sion of chemokine receptors and adhesion molecules by 
the blasts and various cell types residing in the skin (5). 
The mechanism of preferential migration of blasts to the 
skin rather than to other extramedullary sites is likewise 
Table I. Reactivity for selected immunohistochemistry in skin 
biopsies by bone marrow diagnostic group
Diagnosis
Lysozyme Myeloperoxidase CD68
Positive Negative Positive Negative Positive Negative
M0 0 0 0 1 0 0
M1 1 0 1 0 0 0
M2 2 0 0 0 0 0
M4 5 0 3 4 2 0
M5 3 0 1 3 2 0
M7 0 0 0 1 0 0
CMML 3 0 2 0 1 0
MDS 1 0 3 0 0 0
JMML 1 0 1 0 0 0
Unknown 12 1 8 5 9 0
Unclassifiable 0 0 0 3 0 0
Total 28 1 19 17 14 0
CMML: chronic myelomonocytic leukemia; MDS: myelodysplastic 
syndrome; JMML: juvenile myelomonocytic leukemia.







Concordant skin immunohistochemistry/bone marrow flow cytometry
CD4 M4 + +
CD4 M4 + +
CD5 M4 + +
CD33 M5 + +
CD34 M4 – –
CD34 M4 – –
CD34 M5 + +
CD34 M5 – –
CD34 M4 + +
CD56 M5 + +
CD56 M4 + +
CD56 M4 + +
CD117 M4 + +
CD117 M0 – –
Discordant skin immunohistochemistry/bone marrow flow cytometry
CD4 M4 + –
CD34 AML ex CMML – +
CD34 M6a – +
CD117 AML ex CMML – +
Concordant skin immunohistochemistry/bone marrow immunohistochemistry
CD3 M4 – –
CD4 M4 + +
CD7 M4 – –
CD8 M4 – –
CD20 M4 – –
CD30 M4 – –
CD34 M4 – –
CD34 AML NOS – –
CD56 M4 + +
CD56 M5 + +
CD68 M2 + +
AML: acute myeloid leukemia; CMML: chronic myelomonocytic leukemia; 
NOS: nitric oxide synthase.
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unknown, but may be related to the similarity of certain 
features of the microanatomies of both sites, such as the 
rich microvascular background and similar percentage 
of type III collagen and other intermediate filaments. 
Despite the frequency of involvement of the skin by 
AML, large studies of CMS are relatively few. To our 
knowledge, 9 previous studies have appeared in the pe-
er-reviewed English language medical literature within 
the last 20 years (6–14), none of which fully address all 
major questions regarding clinical and pathologic featu-
res, molecular genetic findings, and outcome in CMS. 
In our study, CMS is identified as predominantly 
affecting the elderly, although a broad age range is 
present. This is also reflected in the medical literature 
(6–14). Like us, most series reported a male predomi-
nance, although the study of Kaddu et al. (11) reports 
a predominance of females. Information about risk of 
cutaneous disease based on ethnicity is relatively lack-
ing, probably due to a relative paucity of cases reported 
from North America. In our study, the vast majority of 
patients were Caucasian. Lesions are usually multiple 
and are described as papules, plaques, and/or nodules. 
The torso is most commonly involved, although a wide 
range of body sites has been reported. Our data show 
that the distribution of lesions favors the upper body. 
In all series in which an appropriate level of detail 
was provided  (7–14), the most common bone marrow 
diagnosis was AML, and cases with myelomonocytic 
or monoblastic/monocytic differentiation were promi-
nently represented. When reported, CMS was noted to 
follow the initial bone marrow diagnosis (6, 12, 13), 
though most patients eventually have bone marrow 
involvement. The pattern of skin involvement has been 
described previously (8, 9, 11–13), and Benet et al. 
(13) describe that cases initially presenting in the skin 
have a predilection for diffuse architecture, “high dense 
infiltrate”, large cells, and high mitotic index compared 
to cases with secondary involvement of the skin. This 
finding was not observed in our cases. The reason for 
this is uncertain, but may involve timing of the biopsy 
(longer-standing lesions would presumably have a larger 
number of malignant cells), preferential biopsy of the 
center vs. the leading edge of a lesion, or some other fac-
tor. Moreover, the clinical significance of differentiating 
the de novo vs. secondary cases (which could, of course, 
have been resolved on clinical grounds) is likely of little 
consequence in our patients, since survival for patients 
in our series was almost uniformly poor; patients do not 
appear to have benefitted from recent innovations in 
chemotherapeutic regimens or bone marrow transplant, 
as previous studies performed over a decade ago have 
demonstrated similar findings (8, 11). 
Genetic mutations are not widely reported in cases 
of AML with skin involvement, and are postulated 
to be similar to the commonly occurring cytogenetic 
findings in AMLs occurring in other sites. Notably, a 
high percentage of cases in our series had abnormal con-
ventional cytogenetic findings. In 25% of cases, there 
were multiple numerical and/or structural abnormalities, 
suggestive of evolution of an aggressive clone. Of the 
cases, 25% had trisomy of chromosome 8, a finding 
identified in myeloid sarcomas involving the skin (14) 
and other sites. 
Numerous studies emphasize the challenges in di-
agnosing CMS. In large part, this is due to the historic 
and ongoing problems in distinguishing non-neoplastic 
from neoplastic monocytes and their precursors and the 
relative insensitivity of antibodies such as CD34 and 
CD117 in identifying blasts in the skin. These are, of 
course, related concepts, since the highest percentage 
of cases in all studies, including ours, represent invol-
vement of the skin by AML with monocytic differen-
tiation, either acute myelomonocytic leukemia (FAB: 
M4) or acute monoblastic/monocytic leukemia (FAB: 
M5). It is thus important to identify a battery of im-
munohistochemical markers which distinguish AMLs 
involving the skin from other diseases. In addition, 
it may be of interest to identify those markers which 
successfully identify cases with monocytic differentia-
tion, for several reasons: patients with acute monocytic 
leukemia may have a more aggressive disease course, 
although this is controversial and not uniformly seen 
in all studies (15–19); AMLs with monocytic differen-
tiation may harbor rearrangements involving the MLL 
gene, many of which, with the prominent exception of 
the translocation t (9;11), have been associated with a 
more aggressive disease course; and perhaps most im-
portantly for diagnostic purposes, it may be important 
to the diagnostician to determine if reactivity for a given 
marker is sufficiently specific to identify cases having 
monocytic differentiation. 
In our patients, the antibodies which were most sen-
sitive in detecting cases of CMS, but were unhelpful 
in distinguishing AMLs with monocytic differentiation 
from others and were performed in a sufficient number 
of cases to be assessed were CD43, CD68, and lyso-
zyme. CD43, although highly sensitive, has a broad 
range of expression, including granulocytes, T cells, 
and some malignant B cells (20). Lysozyme, although 
very sensitive for the detection of myeloid disease, is 
relatively nonspecific for distinction of malignancies 
with monocytic differentiation (e.g. M4, M5, chro-
nic myelomonocytic leukemia (CMML)) from other 
leukemias without monocytic differentiation (e.g.M1, 
M2). Myeloperoxidase is frequently negative due to 
the high frequency of AML with monocytic differen-
tiation. CD68 is reportedly similar to lysozyme in sen-
sitivity, and is similarly nonspecific for distinction of 
malignancies with monocytic differentiation (e.g. M4, 
M5 CMML) from other leukemias without monocytic 
differentiation (e.g.M1, M2). We conclude that none 
of the antibodies studied by us is sufficiently specific, 
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either alone or in combination, to distinguish AMLs with 
monocytic differentiation from other AMLs, although 
CD43, lysozyme, and CD68 are most sensitive in dif-
ferentiating CMS from other disorders. 
Also of interest is whether the blast phenotype is 
concordant between the bone marrow and skin popu-
lations, or whether there is a high rate of phenotypic 
discordance, as has been previously reported (14). 
Notably, the earlier study of Cronin et al. (14) does not 
include bone marrow immunohistochemistry, which 
was often employed in our cases in lieu of or in addi-
tion to flow cytometry. Due to the retrospective nature 
of this study, complete and uniform immunophenoty-
pic analysis of all cases was not performed. However, 
our data show that the blast phenotype as assessed by 
immunohistochemistry is highly consistent between 
sites. Four discordant cases were identified by flow 
cytometry comparing flow cytometry of the bone mar-
row and immunohistochemistry of the skin. These 
differences thus may more likely represent differences 
in the techniques such as antibody sensitivities rather 
than a true discrepant phenotype between the skin and 
bone marrow blasts. 
To summarize, CMS is an uncommon malignancy 
which in most cases represents an aggressive manifesta-
tion of AML. Diagnosis can be challenging due to the 
lack of myeloblast-associated antigen expression in 
many cases, and the difficulty in distinguishing mono-
cyte-lineage blasts from neoplastic and non-neoplastic 
mature monocytes, and aberrant expression of CD7 
and/ or CD56. However, the combination of highly 
sensitive (CD43 and lysozyme) and more specific (my-
eloperoxidase, CD68, CD117, and CD34) antibodies 
can aide in the identification of suspected cases. There 
are additional antibodies that are more specific and 
sensitive for use in the setting of a suspected CMS (2). 
Interestingly, the blast phenotype is usually concordant 
between the bone marrow and skin populations. Cytoge-
netic abnormalities were detected in a high percentage 
of cases, consistent with the aggressive behavior of this 
disease. The vast majority of patients died of disease 
within one year of diagnosis. As the clinical data show, 
the majority of patients with this disorder have a prior 
or concomitant history of AML. Thus, diagnosis of 
CMS is multidisciplinary in many cases and is greatly 
facilitated by the clinical history. 
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